First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

Karen A. Autio,C. Higano,Luke T. Nordquist,Leonard Joseph Appleman,Tian Zhang,Xinhua Zhu,Hani M. Babiker,Nicholas J. Vogelzang,Sandip M. Prasad,Michael T. Schweizer,Stephane Billotte,Joseph John Binder,Nora Cavazos,Ruifeng Li,Kam Chan,Helen Kim Cho,Michael R. Dermyer,Robert Hollingsworth,Kenneth A. Kern,Daniel P. Petrylak

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

2021

2612Background: Therapeutic vaccines targeting PC-associated antigens represent attractive approaches in combination with immune checkpoint inhibitors (ICI). Safety/antitumor activity of PF-0675351...

Keywords:

Medicine
Regimen
breakpoint cluster region
Biochemical relapse
first in human
Antigen
Prostate cancer
Cancer research
phase i study
Immunotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations